Related references
Note: Only part of the references are listed.Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody
Ryota Shibaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Management of Immune Checkpoint Inhibitor Toxicities
Quentin Durrechou et al.
Cancer Management and Research (2020)
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
Hazim Bukamur et al.
SOUTHERN MEDICAL JOURNAL (2020)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids
Akihiro Tokunaga et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Jacques Cadranel et al.
EUROPEAN RESPIRATORY REVIEW (2019)
Nivolumab-induced interstitial lung disease in a patient with gastric cancer
Akie Kimura et al.
OXFORD MEDICAL CASE REPORTS (2019)
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors
David F. Heigener et al.
JOURNAL OF THORACIC DISEASE (2018)
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
Teppei Yamaguchi et al.
LUNG CANCER (2018)
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
Bairavi Shankar et al.
JOURNAL OF THORACIC DISEASE (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
Severe pneumonitis after nivolumab treatment in a patient with melanoma
Satoshi Watanabe et al.
ALLERGOLOGY INTERNATIONAL (2016)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
Vascular endothelial growth factor in the lung
NF Voelkel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema
LB Ware et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: A potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia
M Okamoto et al.
BLOOD (2002)
VEGF: an update on biological and therapeutic aspects
N Farrara
CURRENT OPINION IN BIOTECHNOLOGY (2000)
Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema
RJ Kaner et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2000)
Share Paper
